ijms-logo

Journal Browser

Journal Browser

A Commemorative Issue Honoring Biomolecular Scientists in the Post-COVID-19 Pandemic Era

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 20 July 2024 | Viewed by 2726

Special Issue Editor

Special Issue Information

Dear Colleagues,

In this post-COVID-19 pandemic era, it is important to commemorate and celebrate the remarkable role of biomolecular scientists in developing vaccines. The development of effective vaccines for COVID-19 required a deep understanding of the complex interactions of multiple molecular and cellular processes. The successful development of vaccines is a testament to the dedication and hard work of the scientists involved. Celebrating their efforts also helps to raise public awareness about the importance of biomolecular science and research in improving public health and wellbeing. In addition, the fast development of vaccines for such a novel disease provides hope for future pandemics and demonstrates the potential of biomolecular research to address global health challenges. By celebrating the response of biomolecular scientists to developing vaccines for COVID-19, we recognize their contributions to advancing human health and encourage continued investment in the field of biomolecular science.

The aim of this Special Issue is to honor the contributions of biomolecular scientists in responding to COVID-19. The focus of this Special Issue is on computations in biomolecular sciences, which combines the principles of molecular biology, biomolecular science, and computer science to develop new tools and technologies that can be used to analyze, manipulate, and store biological information, as well as develop novel biological tools and applications. Key applications include the design and development of new drugs, vaccines, therapies, diagnostics, and biosensors. For example, by using computational methods to simulate the behavior of biomolecules and their interactions, scientists can optimize the design of drugs to target specific diseases and minimize side effects. In addition, the application of molecular computations helps in the analysis of large-scale genomic and proteomic data to identify patterns and relationships that would be difficult or impossible to detect through traditional experimental methods. This provides insights into the underlying mechanisms of diseases to develop new diagnostic and therapeutic approaches.

We invite manuscripts that focus on research advances, theoretical underpinnings, demonstrations, and applications in the field of computations in biomolecular sciences. Original research articles, methods, communications, reviews, and mini-reviews on, but not limited to, the following topics can be submitted.

  • DNA computing: the use of DNA molecules as a computing substrate, such as programming, to perform complex computational tasks such as pattern recognition and data storage.
  • Molecular simulations of biomolecular interactions: the use of computational tools to generate novel biomolecules and study interactions between biomolecules (e.g., protein–protein and DNA–protein interactions).
  • RNA folding algorithms: development of algorithms that can predict the structure of RNA molecules, which can be used to study the function of RNA and its role in diseases.
  • Protein structure prediction: development of methods to predict the structure of proteins based on their amino acid sequences, which can be used to study the function of proteins and their interactions with other molecules.
  • Molecular modeling: the use of computational methods to simulate the motion and interactions of biological molecules, providing insights into the dynamic behavior of biological systems.
  • Systems biology: the integration of computational methods with experimental data to study the behavior of biological systems at the molecular, cellular, and organismal levels, and to gain insights into complex biological processes.
  • Synthetic biology: the design and construction of new biological systems for specific applications, such as the production of biofuels/bioproducts or the development of new diagnostic and therapeutic tools.
  • Metabolic network analysis: the use of computational methods to study the metabolic processes of cells and organisms, providing insights into the biochemical pathways involved in cellular metabolism and the regulation of cellular function.

Dr. Michael Danquah
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

18 pages, 3588 KiB  
Article
Baseline Gut Microbiome Signatures Correlate with Immunogenicity of SARS-CoV-2 mRNA Vaccines
by Lauren Daddi, Yair Dorsett, Tingting Geng, Suresh Bokoliya, Hanshu Yuan, Penghua Wang, Wanli Xu and Yanjiao Zhou
Int. J. Mol. Sci. 2023, 24(14), 11703; https://doi.org/10.3390/ijms241411703 - 20 Jul 2023
Cited by 5 | Viewed by 1479
Abstract
The powerful immune responses elicited by the mRNA vaccines targeting the SARS-CoV-2 Spike protein contribute to their high efficacy. Yet, their efficacy can vary greatly between individuals. For vaccines not based on mRNA, cumulative evidence suggests that differences in the composition of the [...] Read more.
The powerful immune responses elicited by the mRNA vaccines targeting the SARS-CoV-2 Spike protein contribute to their high efficacy. Yet, their efficacy can vary greatly between individuals. For vaccines not based on mRNA, cumulative evidence suggests that differences in the composition of the gut microbiome, which impact vaccine immunogenicity, are some of the factors that contribute to variations in efficacy. However, it is unclear if the microbiome impacts the novel mode of immunogenicity of the SARS-CoV-2 mRNA vaccines. We conducted a prospective longitudinal cohort study of individuals receiving SARS-CoV-2 mRNA vaccines where we measured levels of anti-Spike IgG and characterized microbiome composition, at pre-vaccination (baseline), and one week following the first and second immunizations. While we found that microbial diversity at all timepoints correlated with final IgG levels, only at baseline did microbial composition and predicted function correlate with vaccine immunogenicity. Specifically, the phylum Desulfobacterota and genus Bilophila, producers of immunostimulatory LPS, positively correlated with IgG, while Bacteroides was negatively correlated. KEGG predicted pathways relating to SCFA metabolism and sulfur metabolism, as well as structural components such as flagellin and capsular polysaccharides, also positively correlated with IgG levels. Consistent with these findings, depleting the microbiome with antibiotics reduced the immunogenicity of the BNT162b2 vaccine in mice. These findings suggest that gut microbiome composition impacts the immunogenicity of the SARS-CoV-2 mRNA vaccines. Full article
Show Figures

Figure 1

Review

Jump to: Research

19 pages, 2159 KiB  
Review
Lumican, a Multifunctional Cell Instructive Biomarker Proteoglycan Has Novel Roles as a Marker of the Hypercoagulative State of Long Covid Disease
by Margaret M. Smith and James Melrose
Int. J. Mol. Sci. 2024, 25(5), 2825; https://doi.org/10.3390/ijms25052825 - 29 Feb 2024
Viewed by 942
Abstract
This study has reviewed the many roles of lumican as a biomarker of tissue pathology in health and disease. Lumican is a structure regulatory proteoglycan of collagen-rich tissues, with cell instructive properties through interactions with a number of cell surface receptors in tissue [...] Read more.
This study has reviewed the many roles of lumican as a biomarker of tissue pathology in health and disease. Lumican is a structure regulatory proteoglycan of collagen-rich tissues, with cell instructive properties through interactions with a number of cell surface receptors in tissue repair, thereby regulating cell proliferation, differentiation, inflammation and the innate and humoral immune systems to combat infection. The exponential increase in publications in the last decade dealing with lumican testify to its role as a pleiotropic biomarker regulatory protein. Recent findings show lumican has novel roles as a biomarker of the hypercoagulative state that occurs in SARS CoV-2 infections; thus, it may also prove useful in the delineation of the complex tissue changes that characterize COVID-19 disease. Lumican may be useful as a prognostic and diagnostic biomarker of long COVID disease and its sequelae. Full article
Show Figures

Figure 1

Back to TopTop